Canadian equity crowdfunding launch for micro-needle technology
The equity crowdfunding campaign will concentrate first on animal clinical trials, followed by human clinical trials
PKA SoftTouch Corp. of Lakefield, Ont., launched on April 2 a public equity crowdfunding campaign for its patented Micro-needle technology that may play a key role in delivering a vaccine to battle COVID-19.
“During this time of a global pandemic, the need to create fast painless vaccine delivery in pre-measured quantities has never been greater,” said Dick Crawford, PKA board chair and CEO in a prepared statement. “We need to move quickly.”
On March 31, Prime Minister Justin Trudeau called for “made-in-Canada solutions” for desperately needed medical supplies in the face of COVID-19. During his daily briefing, the prime minister predicted “made-in-Canada supply chains” will emerge to get supplies into the hands of healthcare professionals.
Crawford said the thumb-sized Micro-Needle has the potential to deliver pain medication and insulin as well as vaccines with painless delivery and instant disposability, eliminating fear, needle phobia and sharps disposal issues.
The equity crowdfunding campaign will concentrate first on animal clinical trials, followed quickly by human clinical trials.
The campaign is hosted by Vancouver-based equity crowdfunding platform Frontfundr.
Clinical trials will be conducted at the University of Guelph, Ont., and Southlake Regional Health Centre, Newmarket, Ont.